A citation-based method for searching scientific literature

Jessica Buck, Patrick J C Dyer, Hilary Hii, Brooke Carline, Mani Kuchibhotla, Jacob Byrne, Meegan Howlett, Jacqueline Whitehouse, Martin A Ebert, Kerrie L McDonald, Nicholas G Gottardo, Raelene Endersby. Front Mol Biosci 2021
Times Cited: 3







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
Maddison Rose, Joshua T Burgess, Kenneth O'Byrne, Derek J Richard, Emma Bolderson. Front Cell Dev Biol 2020
82
66



Repair of strand breaks by homologous recombination.
Maria Jasin, Rodney Rothstein. Cold Spring Harb Perspect Biol 2013
486
33

The BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients.
Mohamed Saleem, Mohd Bazli Ghazali, Md Azlan Mohamed Abdul Wahab, Narazah Mohd Yusoff, Hakimah Mahsin, Ch'ng Ewe Seng, Imran Abdul Khalid, Mohd Nor Gohar Rahman, Badrul Hisham Yahaya. Adv Exp Med Biol 2020
4
33


Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Kit Man Chai, Chih-Yen Wang, Hung-Jiun Liaw, Kuan-Min Fang, Chung-Shi Yang, Shun-Fen Tzeng. Oncotarget 2014
29
33

PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials.
Dalia Kamel, Christopher Gray, Jagdeep Singh Walia, Vikaash Kumar. Curr Drug Targets 2018
68
33

BRCA2 is required for neurogenesis and suppression of medulloblastoma.
Pierre-Olivier Frappart, Youngsoo Lee, Jayne Lamont, Peter J McKinnon. EMBO J 2007
80
33

Genetic and Genomic Advances in Breast Cancer Diagnosis and Treatment.
Tammy L Walker-Smith, Jessica Peck. Nurs Womens Health 2019
2
50


Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, Domenico Milano, Elisa Giacomini, Federico Falchi, Andrea Balboni, Marcella Manerba, Fulvia Farabegoli, Francesca De Franco,[...]. Eur J Med Chem 2019
17
33

Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights.
Soumen Khatua, Anne Song, Divyaswathi Citla Sridhar, Stephen C Mack. Curr Neuropharmacol 2018
16
33

PARP inhibitor resistance: the underlying mechanisms and clinical implications.
He Li, Zhao-Yi Liu, Nayiyuan Wu, Yong-Chang Chen, Quan Cheng, Jing Wang. Mol Cancer 2020
62
33

Mutations in the RAD54 recombination gene in primary cancers.
M Matsuda, K Miyagawa, M Takahashi, T Fukuda, T Kataoka, T Asahara, H Inui, M Watatani, M Yasutomi, N Kamada,[...]. Oncogene 1999
68
33

Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
Elena Ratner, Mohan Bala, Melinda Louie-Gao, Ebru Aydin, Sebastien Hazard, Priscilla K Brastianos. Gynecol Oncol 2019
17
33

CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer.
Hongbao Yang, Xiaobo Li, Qingtao Meng, Hao Sun, Shenshen Wu, Weiwei Hu, Guilai Liu, Xianjing Li, Yong Yang, Rui Chen. Mol Cancer 2020
72
33

Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.
L Golmard, C Delnatte, A Laugé, V Moncoutier, C Lefol, K Abidallah, H Tenreiro, F Copigny, M Giraudeau, C Guy,[...]. Oncogene 2016
21
33

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Jacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, Paul W G Wijnhoven, Valeria Follia, Neil James, Paul M Farrington, Ankur Karmokar, Sophie E Willis, Jonathan Cairns,[...]. Nat Commun 2019
82
33

Evaluating In Vitro DNA Damage Using Comet Assay.
Yanxin Lu, Yang Liu, Chunzhang Yang. J Vis Exp 2017
38
33


DNA damage and repair measured by comet assay in cancer patients.
Pavel Vodicka, Sona Vodenkova, Alena Opattova, Ludmila Vodickova. Mutat Res Genet Toxicol Environ Mutagen 2019
18
33

Clinical assays for assessment of homologous recombination DNA repair deficiency.
Elizabeth H Stover, Katherine Fuh, Panagiotis A Konstantinopoulos, Ursula A Matulonis, Joyce F Liu. Gynecol Oncol 2020
19
33


Conformational flexibility and oligomerization of BRCA2 regions induced by RAD51 interaction.
Arshdeep Sidhu, Małgorzata Grosbart, Humberto Sánchez, Bram Verhagen, Nick L L van der Zon, Dejan Ristić, Sarah E van Rossum-Fikkert, Claire Wyman. Nucleic Acids Res 2020
5
33

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
David E Cohn, Kenneth H Kim, Kimberly E Resnick, David M O'Malley, J Michael Straughn. J Clin Oncol 2011
136
33

Metformin and reduced risk of cancer in diabetic patients.
Josie M M Evans, Louise A Donnelly, Alistair M Emslie-Smith, Dario R Alessi, Andrew D Morris. BMJ 2005
33

Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line.
Jacob Bornstein, Shlomi Sagi, Amer Haj, Jeffrey Harroch, Fuad Fares. Gynecol Oncol 2005
23
33

Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors.
Sören Weidemann, Pauline Gagelmann, Natalia Gorbokon, Maximilian Lennartz, Anne Menz, Andreas M Luebke, Martina Kluth, Claudia Hube-Magg, Niclas C Blessin, Christoph Fraune,[...]. Biomedicines 2021
9
33

LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway.
Y Jin, S-J Feng, S Qiu, N Shao, J-H Zheng. Eur Rev Med Pharmacol Sci 2017
121
33

Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?
Daniel Martin Klotz, Pauline Wimberger. Arch Gynecol Obstet 2017
31
33

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
Anne M Schultheis, Georg Lurje, Katrin E Rhodes, Wu Zhang, Dongyun Yang, Agustin A Garcia, Robert Morgan, David Gandara, Sidney Scudder, Amit Oza,[...]. Clin Cancer Res 2008
146
33

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.
Adam D Steg, Kerri S Bevis, Ashwini A Katre, Angela Ziebarth, Zachary C Dobbin, Ronald D Alvarez, Kui Zhang, Michael Conner, Charles N Landen. Clin Cancer Res 2012
250
33

CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Yeongseon Byeon, Jeong-Won Lee, Whan Soo Choi, Ji Eun Won, Ga Hee Kim, Min Gi Kim, Tae In Wi, Jae Myeong Lee, Tae Heung Kang, In Duk Jung,[...]. Cancer Res 2018
42
33

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Deborah K Armstrong, Brian Bundy, Lari Wenzel, Helen Q Huang, Rebecca Baergen, Shashikant Lele, Larry J Copeland, Joan L Walker, Robert A Burger. N Engl J Med 2006
33

Statin use and female reproductive organ cancer risk in a large population-based setting.
Onchee Yu, Denise M Boudreau, Diana S M Buist, Diana L Miglioretti. Cancer Causes Control 2009
34
33

Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.
Ruey-Shyang Soong, Liwen Song, Janson Trieu, Sung Yong Lee, Liangmei He, Ya-Chea Tsai, T-C Wu, Chien-Fu Hung. PLoS One 2014
14
33

The Effect of Histological Subtypes on Outcomes of Stage IV Epithelial Ovarian Cancer.
Juan Zhou, San-Gang Wu, Jun Wang, Jia-Yuan Sun, Zhen-Yu He, Xin Jin, Wen-Wen Zhang. Front Oncol 2018
13
33

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.
Sanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, Laura L Fernandes, Shenghui Tang, Hisani N Horne, Jinzhong Liu, Chao Liu, Sarah J Schrieber, Jingyu Yu,[...]. Clin Cancer Res 2017
84
33

AMPK: a nutrient and energy sensor that maintains energy homeostasis.
D Grahame Hardie, Fiona A Ross, Simon A Hawley. Nat Rev Mol Cell Biol 2012
33

Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Jung-Min Lee, Christina M Annunziata, John L Hays, Liang Cao, Peter Choyke, Minshu Yu, Daniel An, Ismail Baris Turkbey, Lori M Minasian, Seth M Steinberg,[...]. Gynecol Oncol 2020
5
33

Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Rongrong Zhang, Ping Zhang, Hong Wang, Dongming Hou, Wentao Li, Guishan Xiao, Chenwei Li. Stem Cell Res Ther 2015
53
33

Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer.
Kui Wang, Wei Gao, Qianhui Dou, Haining Chen, Qifu Li, Edouard C Nice, Canhua Huang. Autophagy 2016
29
33

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.
R Rattan, S Giri, L C Hartmann, V Shridhar. J Cell Mol Med 2011
161
33

Autophagy is required for glucose homeostasis and lung tumor maintenance.
Gizem Karsli-Uzunbas, Jessie Yanxiang Guo, Sandy Price, Xin Teng, Saurabh V Laddha, Sinan Khor, Nada Y Kalaany, Tyler Jacks, Chang S Chan, Joshua D Rabinowitz,[...]. Cancer Discov 2014
329
33

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
Jeffrey A How, Amir A Jazaeri, Bryan Fellman, Molly S Daniels, Suzanna Penn, Cara Solimeno, Ying Yuan, Kathleen Schmeler, Jerry S Lanchbury, Kirsten Timms,[...]. Cancers (Basel) 2021
7
33

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Scott M Wilhelm, Christopher Carter, Liya Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick Vincent, Mark McHugh,[...]. Cancer Res 2004
33

Aflibercept--a decoy VEGF receptor.
Kristen K Ciombor, Jordan Berlin. Curr Oncol Rep 2014
30
33

Inhibitory effects of bisphosphonates on the proliferation of human ovarian cancer cell lines and the mechanism.
Junko Hirata, Yoshihiro Kikuchi, Kazuya Kudoh, Tsunekazu Kita, Hiroshi Seto. Med Chem 2006
7
33

Iron oxide magnetic nanoparticles as antimicrobials for therapeutics.
Lucas de Alcântara Sica de Toledo, Hélen Cássia Rosseto, Marcos Luciano Bruschi. Pharm Dev Technol 2018
27
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.